Drug name - Farydak
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7989494 | SECURA | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide |
Jan, 2028
(5 years from now) | |
| CN102584673B | SECURA | Polymorphs Of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide |
Jun, 2027
(4 years from now) | |
| CN101641328B | SECURA | Polymorphs Of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide |
Jun, 2027
(4 years from now) | |
| CN101641328A | SECURA | Polymorphs Of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide |
Jun, 2027
(4 years from now) | |
| CN102584673A | SECURA | Polymorphic Substance Of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Ly) Ethyl] Amino] Methyl] Phenyl]-2E-2-Acrylamide |
Jun, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883842 | SECURA | Use of HDAC inhibitors for the treatment of myeloma |
Jun, 2028
(5 years from now) | |
Drugs and Companies using PANOBINOSTAT LACTATE ingredient
Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 10MG BASE | CAPSULE;ORAL | Discontinued |
| EQ 15MG BASE | CAPSULE;ORAL | Discontinued |
| EQ 20MG BASE | CAPSULE;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.